Urothelial Cancer clinical trials

Explore recruiting urothelial cancer clinical trials.

Recruiting urothelial cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Urothelial Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive mitomycin-C (EMDA-MMC) in patients with high-risk non-muscle-invasive bladder carcinoma (FINNBLADDER 10)

Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLA

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Urothelial Cancer trials by city

Urothelial Cancer in Toronto Urothelial Cancer in Vancouver Urothelial Cancer in Montreal Urothelial Cancer in Calgary Urothelial Cancer in Edmonton Urothelial Cancer in Ottawa Urothelial Cancer in Winnipeg Urothelial Cancer in Quebec City Urothelial Cancer in Hamilton Urothelial Cancer in Kitchener Urothelial Cancer in London Urothelial Cancer in Halifax Urothelial Cancer in New York Urothelial Cancer in Los Angeles Urothelial Cancer in Chicago Urothelial Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease